ABSTRACT
A 65-year-old man was referred to our hospital because of a fever and cough 19 years after chemoradiotherapy for small-cell lung cancer(SCLC)in the right middle lobe. Computed tomography(CT)revealed a normal right middle lobe, but found pneumonia and a tumor at the bronchial entrance of the right upper lobe. After treating the pneumonia with antibiotics and prednisolone, transbronchial biopsies(TBBs)revealed the tumor to be squamous cell carcinoma(SCC). Eight lines of chemotherapy including immune checkpoint inhibitors(ICIs)were completed with a 42-month survival following the initiation of chemotherapy for SCC, after which he ultimately died of hemoptysis. Survival of over 10 years from small- cell cancer is rare. We herein report the prognosis of SCLC and the treatment of subsequent primary lung cancer.
Subject(s)
Carcinoma, Small Cell , Carcinoma, Squamous Cell , Lung Neoplasms , Small Cell Lung Carcinoma , Aged , Anti-Bacterial Agents/therapeutic use , Carcinoma, Small Cell/drug therapy , Carcinoma, Squamous Cell/drug therapy , Chemoradiotherapy , Humans , Immune Checkpoint Inhibitors , Lung/metabolism , Lung/pathology , Lung Neoplasms/drug therapy , Lung Neoplasms/metabolism , Male , Prednisolone/therapeutic use , Small Cell Lung Carcinoma/drug therapyABSTRACT
A patient with multiple endocrine neoplasia type 1 (MEN1) developed a mediastinal seminoma. The patient was a 46-year-old man who presented with respiratory symptoms. A diagnosis of mediastinal seminoma was pathologically confirmed and a complete remission was achieved by chemotherapy. During his hospital stay, hyperparathyroidism and multiple pancreatic tumors associated with hypergastrinemia were found. A diagnosis of MEN1 was made genetically. Although patients with MEN1 manifest a variety of neoplastic disorders, no cases of concurrent seminoma and MEN1 have previously been reported. In addition, no etiological relationship between seminoma and MEN1 has yet been reported.
Subject(s)
Mediastinal Neoplasms/diagnosis , Multiple Endocrine Neoplasia Type 1/diagnosis , Neoplasms, Multiple Primary/diagnosis , Seminoma/diagnosis , Humans , Male , Mediastinal Neoplasms/drug therapy , Mediastinal Neoplasms/pathology , Middle Aged , Neoplasms, Multiple Primary/drug therapy , Remission Induction , Seminoma/drug therapy , Seminoma/pathologyABSTRACT
A 59-year-old woman was diagnosed with incomplete type Behçet's syndrome in 1994. The patient was hospitalized with pharyngitis and fever in August 2000, and was treated using non-steroidal anti-inflammatory drugs (NSAIDs). Symptoms improved and she was discharged. After only 3 weeks, she reported swallowing disturbance due to retrosternal pain. Esophagoscopy revealed multiple shallow oval ulcerations in the middle esophagus. Colonoscopy revealed aphthous lesions in the rectum. Prednisolone (0.5 mg/kg) was initiated for treatment of esophageal involvement. Symptoms gradually improved and subsequent esophagoscopy revealed complete healing of esophageal ulcerations.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Behcet Syndrome/drug therapy , Esophageal Diseases/drug therapy , Prednisolone/therapeutic use , Ulcer/drug therapy , Behcet Syndrome/complications , Endoscopy , Esophageal Diseases/diagnosis , Esophageal Diseases/etiology , Female , Humans , Middle Aged , Rectal Diseases/diagnosis , Rectal Diseases/drug therapy , Rectal Diseases/etiology , Treatment Outcome , Ulcer/diagnosis , Ulcer/etiologyABSTRACT
The role of systemic chemotherapy and optimal regimen in thymic carcinoma remains uncertain. We evaluated the clinical responsiveness of ADOC (cisplatin, doxorubicin, vincristine, and cyclophosphamide) chemotherapy for advanced thymic carcinoma that have distant metastatic or unresectable lesions. From 1996 to 2000, we treated eight cases of thymic carcinoma. According to the classification by Masaoka et al., the clinical stage in one case was IVa, whereas the others were IVb. Histologic subtypes were as follows: four cases were squamous cell carcinoma, two cases were undifferentiated, and two were small-cell carcinoma. All patients received 50 mg/m2 of cisplatin and 40 mg/m2 of doxorubicin intravenously on day 1, 0.6 mg/m2 of vincristine intravenously on day 3, and 700 mg/m2 of cyclophosphamide intravenously on day 4, ADOC regimen, respectively, at 3- to 4-week intervals. Six patients obtained a partial response after ADOC chemotherapy and the overall clinical response rate was 75%. There were no life-threatening side effects noted. Cisplatin plus VP-16 chemotherapy (PVP) was performed in three cases before the ADOC regimen, but PVP chemotherapy did not show beneficial effects in two patients. Median survival time was 19 months. ADOC chemotherapy appears to have significant activity against thymic carcinoma.
